Want to see SRPT full AI Analyst Report?
SRPT Stock Chart & Stats
$18.92
-$0.20(-1.26%)
At close: 4:00 PM EDT
$18.92
-$0.20(-1.26%)
Day’s Range― - ―
52-Week Range$14.68 - $24.68
Previous CloseN/A
Volume2.14M
Average Volume (3M)3.07M
Market Cap
$1.87B
Enterprise Value$2.15B
Total Cash (Recent Filing)$788.49M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 04, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding105,627,020
10 Day Avg. Volume3,790,367
30 Day Avg. Volume3,066,687
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.86
Enterprise Value/Ebitda-147.56
Forecast
1Y Price Target
$21.53Price Target Upside13.81% Upside
Rating ConsensusHold
Number of Analyst Covering17
EPS Forecast (FY)3.14
Revenue Forecast (FY)$1.84B
Bulls Say, Bears Say
Bulls Say
Durable PMO FranchiseThe PMO franchise provides an established commercial base within DMD, supported by high adherence and a sizable treated population. Its 75% quarterly gross margin and stable demand can help sustain funding for pipeline development while ELEVIDYS adoption evolves.
Improved Operating DisciplineRecent operating profitability and substantial expense reductions show that Sarepta can improve earnings through tighter cost control and portfolio prioritization. This strengthens operating leverage and creates a more resilient foundation for investing in commercial and clinical programs.
Broader ELEVIDYS Clinical SupportEvidence of sustained functional benefit across older ambulatory patients broadens support for ELEVIDYS beyond younger populations. If maintained through continued follow-up, this can reinforce physician confidence, extend the therapy's addressable use, and support longer-term franchise durability.
Bears Say
ELEVIDYS Revenue PressureThe decline in ELEVIDYS demand is significant because the therapy is central to Sarepta's growth outlook. Management expects Q3 ELEVIDYS revenue and second-half product revenue to be lower, creating an ongoing risk that commercial expansion will not offset near-term weakness.
Persistent Cash BurnContinued negative operating and free cash flow means Sarepta has not yet demonstrated durable self-funding economics. Persistent cash burn can constrain flexibility for clinical development, commercial investment, and other capital allocation decisions if profitability remains inconsistent.
Regulatory And Program ConstraintsDelayed cohort 8 safety data postpones regulatory discussions tied to nonambulatory labeling and leaves important program decisions unresolved. The LGMD clinical hold further limits pipeline progress, increasing dependence on DMD execution and successful regulatory outcomes.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $14.68 and its highest was $24.68 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.87B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 14 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.217 by -$0.267.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.07.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,627,020 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.217. Following the earnings report the stock price went up 5.336%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.53 (13.81% Upside)
$21.53 (13.81% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 74%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.83%
12-Months-Change
Fundamentals
Return on Equity
-9.96%
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$21.53
▲(13.81% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
uniQure
―
Wave Life Sciences
―
Solid Biosciences
―
Taysha Gene Therapies
―
Ownership Overview
6.08% Insiders
16.96% Mutual Funds
0.21% Other Institutional Investors
45.70% Public Companies and
Individual Investors